炎症性肠病患者骨折风险:1964至2014年全国性人群队列研究
该全国性人群队列研究纳入83435例新发炎症性肠病(IBD)患者和825817名参照个体,随访1964至2014年。IBD患者髋部骨折风险升高(HR=1.42,95%CI 1.36-1.48),任何骨折风险亦升高(HR=1.18,95%CI 1.15-1.20);无皮质类固醇暴露者关联不显著(HR=1.11,95%CI 0.86-1.44)。
要点
- IBD患者髋部骨折风险升高(HR=1.42,95%CI 1.36-1.48),任何骨折风险升高(HR=1.18,95%CI 1.15-1.20)。
- 无皮质类固醇暴露的IBD个体髋部骨折关联不显著(HR=1.11,95%CI 0.86-1.44)。
- 皮质类固醇与髋部骨折的关联仅在老年(>60岁)IBD患者中显著(P<0.001)。
核心结论
- IBD(CD和UC)与髋部骨折及任何骨折风险增加相关,但无皮质类固醇治疗史者无此关联。
- 皮质类固醇与髋部骨折的关联仅限于老年IBD患者。
研究设计与样本
- 全国性人群队列研究,纳入83435例新发IBD患者(UC n=50162,CD n=26763,未分类IBD n=6510)和825817名参照个体,时间跨度为1964至2014年。
- 采用多变量Cox回归估计髋部骨折和任何骨折的风险比(HR),并分析累积皮质类固醇暴露的关联。
主要发现
- IBD患者随访1,225,415人年期间发生2,491例首次髋部骨折(203/100,000人年),参照个体随访12,405,642人年期间发生20,583例髋部骨折(159/100,000人年),对应HR=1.42(95%CI 1.36-1.48)。
- CD患者髋部骨折风险高于UC患者(P<0.001)。
- IBD与任何骨折相关(HR=1.18,95%CI 1.15-1.20)。
- 自免疫调节剂或生物制剂引入以来,髋部骨折的风险比未发生变化。
- 累积皮质类固醇暴露增加与IBD和非IBD个体髋部骨折均相关(P<0.001),但仅在老年(>60岁)IBD患者中显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Most studies on fractures in inflammatory bowel disease (IBD) are based on patients from tertiary centers or patients followed up before the introduction of immunomodulators or biologics. In addition, the role of corticosteroids in fracture risk has rarely been examined. METHODS: We conducted a nationwide population-based cohort study of 83,435 patients with incident IBD (ulcerative colitis [UC]: n = 50,162, Crohn's disease [CD]: n = 26,763, and IBD unclassified: 6,510) and 825,817 reference individuals from 1964 to 2014. Using multivariable Cox regression, we estimated hazard ratios (HRs) for hip fracture and any fracture and the association with cumulative corticosteroid exposure. RESULTS: During 1,225,415 person-years of follow-up in patients with IBD, there were 2,491 first-time hip fractures (203/100,000 person-years) compared with 20,583 hip fractures during 12,405,642 person-years in reference individuals (159/100,000 person-years). This corresponded to an HR of 1.42 (95% confidence interval [CI] = 1.36-1.48). The risk for hip fracture was higher in CD compared with UC (P < 0.001). Inflammatory bowel disease was also associated with any fracture (IBD: HR = 1.18; 95% CI = 1.15-1.20). Hazard ratios for hip fracture had not changed since the introduction of immunomodulators or biologics. Increasing exposure to corticosteroids was associated with hip fracture in both IBD and non-IBD individuals (P < 0.001), but only in elderly (>60 years) patients with IBD. The association between IBD and hip fracture was nonsignificant among individuals without corticosteroids (HR = 1.11; 95% CI = 0.86-1.44). CONCLUSIONS: Inflammatory bowel disease (CD and UC) is associated with an increased risk of hip fracture and any fracture, but not in individuals without a history of corticosteroid treatment. The association between corticosteroids and hip fracture was restricted to elderly patients with IBD.
引用
- Ludvigsson JF, Mahl M, Sachs MC, et al. Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014. Am J Gastroenterol. 2019. PMID: 30730858. doi:10.14309/ajg.0000000000000062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。